Abstract
The therapeutic efficacy of three different antiblastic regimens was tested in patients affected by primary or secondary liver cancer. The association of cyclophosphamide and adriamycin gave the best results, despite no partial remission observed with any treatment. As regards the efficacy of antiblastic therapy in this type of tumor, we must conclude that the only detectable effect is a transient improvement of the course of the disease.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Hepatocellular / drug therapy*
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Female
-
Gastrointestinal Neoplasms / pathology
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary
-
Male
-
Middle Aged
Substances
-
Doxorubicin
-
Cyclophosphamide